Derek (More Plates More Dates) TRT: Comparison to Similar Public Figures

Who Is Derek from More Plates More Dates?

Derek is a Canadian fitness educator who built the More Plates More Dates brand into one of the largest TRT and performance-enhancing drug (PED) education platforms on YouTube, with over 1.9 million subscribers as of early 2025. His content focuses on pharmacology, bloodwork interpretation, and hormone optimization. He has disclosed on multiple occasions that he personally uses testosterone replacement therapy.

His channel sits at an unusual intersection: it is educational rather than purely lifestyle content, and Derek frequently cites published research, which has made him a reference point for a large segment of the TRT-curious population. That reach carries both informational value and clinical responsibility.

What Derek Has Said Publicly

Derek has stated in multiple YouTube videos and podcast appearances that he began TRT after experiencing symptoms consistent with hypogonadism, including fatigue, low libido, and poor recovery, alongside bloodwork showing testosterone below the clinical threshold. He has not disclosed a specific numerical value publicly in the sources reviewed for this article. Any figure circulating online without a direct, verified quote from Derek himself should be treated as inference.

The Endocrine Society defines biochemical hypogonadism as a morning total testosterone consistently below 300 ng/dL on at least two separate measurements, paired with clinical symptoms. [1] Derek's described symptom pattern aligns with that diagnostic framework, though his personal labs remain private.

The Educational Framing He Uses

Derek consistently frames his TRT discussions in a context of harm reduction and informed decision-making rather than promotion. He discusses blood panel monitoring, hematocrit management, and the difference between TRT doses (100 to 200 mg/week of testosterone cypionate or enanthate in most clinical protocols) and supraphysiologic bodybuilding doses. That distinction matters clinically. The Endocrine Society guideline explicitly states that TRT "should be prescribed to men with classic androgen deficiency syndromes" and not for age-related decline alone, absent confirmed hypogonadism. [1]

Clinical Background on Testosterone Replacement Therapy

TRT is a well-studied intervention for confirmed hypogonadism. The 2018 Endocrine Society Clinical Practice Guideline recommends testosterone therapy for men with symptomatic hypogonadism, defined by both low serum testosterone and characteristic symptoms. [1] The guideline recommends against universal screening in asymptomatic men and notes that the goal of therapy is to restore testosterone to mid-normal range, roughly 400 to 700 ng/dL in most clinical protocols.

Efficacy Data from Controlled Trials

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with total testosterone below 275 ng/dL, found that testosterone treatment for one year significantly improved sexual function, physical capacity, and mood compared to placebo. [2] The sexual function trial showed a mean increase in the Psychosexual Daily Questionnaire score of 2.4 points in the testosterone group versus 0.5 points in the placebo group (P<0.001). [2]

A 2020 meta-analysis published in JAMA Network Open, covering 35 randomized controlled trials and 5,601 participants, found that testosterone therapy improved lean body mass by a mean of 1.9 kg and reduced fat mass by 1.6 kg compared to placebo, with the greatest effects in men with baseline testosterone below 300 ng/dL. [3]

Monitoring Requirements

Standard clinical monitoring during TRT includes hematocrit at 3 and 6 months (target below 54%), PSA at baseline and 3 to 12 months in men over 40, and testosterone levels checked 3 to 6 months after initiation to confirm mid-normal range. [1] Derek has discussed all three monitoring parameters on his channel, which reflects adherence to mainstream clinical guidance rather than deviation from it.

Comparison to Similar Public Figures

Several other fitness-education influencers and public figures have disclosed TRT or discussed their hormone therapy publicly. Comparing their approaches provides useful context for understanding where Derek's disclosures sit on the spectrum.

Thomas DeLauer

Thomas DeLauer, a nutrition and fitness educator with approximately 3.5 million YouTube subscribers, has discussed testosterone optimization in interviews but has been less explicit than Derek about confirmed hypogonadism diagnoses or specific protocols. He tends to frame hormone health in terms of lifestyle optimization, including diet and fasting, rather than pharmaceutical TRT. The framing difference is clinically meaningful: lifestyle interventions can raise testosterone by modest amounts in obese or metabolically unhealthy men, but they do not substitute for TRT in confirmed hypogonadism. A 2016 systematic review in the European Journal of Endocrinology found that weight loss through caloric restriction raised total testosterone by approximately 2.9 nmol/L (roughly 84 ng/dL) in overweight and obese men. [4] That shift may move someone from the hypogonadal range into low-normal but typically does not reach mid-normal without pharmacological support if the baseline is substantially below 300 ng/dL.

Dr. Andrew Huberman

Dr. Andrew Huberman, a Stanford neuroscientist and host of the Huberman Lab podcast, disclosed in a 2022 podcast episode that he uses testosterone replacement therapy. He has discussed his bloodwork publicly, describing testosterone levels in the high-normal range achieved through TRT. Huberman's disclosures tend to be framed around neuroscience and cognitive performance in addition to physical health, and he has cited peer-reviewed literature on androgen receptor density and neuroplasticity in those discussions. His reach, estimated at over 3 million podcast subscribers, makes his disclosures particularly influential.

From a clinical standpoint, Huberman's and Derek's disclosed use cases share a common thread: both men describe confirmed or inferred hypogonadism, structured monitoring, and doses consistent with replacement rather than supraphysiologic enhancement. That is a clinically important distinction. The FDA-approved prescribing information for testosterone cypionate specifies a replacement range of 200 mg every two weeks for hypogonadism, though most current clinical practice uses more frequent, smaller doses to maintain stable serum levels. [5]

Ben Greenfield

Ben Greenfield, a biohacker and endurance athlete, has discussed peptide therapies, growth hormone secretagogues, and hormone optimization extensively on his podcast. His disclosures include testosterone use, though often in combination with other compounds, and framed strongly through a longevity and biohacking lens. The clinical concern with that framing is that it can normalize stack complexity that goes well beyond what published guidelines endorse for hypogonadism management. The Endocrine Society guideline does not recommend growth hormone therapy in men simply because their IGF-1 levels are in the low-normal range without confirmed GH deficiency. [1]

How Derek Differs from This Peer Group

The table below summarizes how Derek's publicly disclosed approach compares to the three peers above across five clinical dimensions. This framework was developed by the HealthRX medical team based on publicly available statements from each figure. It is not a clinical assessment of any individual.

| Dimension | Derek (MPMD) | Andrew Huberman | Thomas DeLauer | Ben Greenfield | |---|---|---|---|---| | Hypogonadism diagnosis disclosed | Yes (self-reported, symptoms plus labs) | Yes (self-reported) | Not explicitly | Partial disclosure | | Specific protocol details shared | Yes (dose ranges, injection frequency) | Partial | Rarely | Yes, extensive | | Bloodwork monitoring discussed | Yes, detailed | Yes | Occasionally | Yes | | Supraphysiologic use acknowledged | Yes (historical, clearly labeled) | Not publicly | Not applicable | Sometimes ambiguous | | Guideline alignment of framing | High | High | Moderate | Variable |

Derek's distinguishing characteristic within this peer group is his explicit acknowledgment of the line between replacement therapy and enhancement. He has publicly discussed his own history with higher-dose use before TRT, which adds a transparency layer that most peers in this space do not offer. That transparency, while not a clinical credential, reduces the risk that his audience conflates replacement with enhancement.

The Hypogonadism Diagnosis Question

Whether any public figure genuinely qualifies for TRT under clinical guidelines is not determinable from public disclosures alone. A proper hypogonadism diagnosis requires, per the Endocrine Society, at least two morning fasting testosterone measurements on separate days, evaluation of LH and FSH to distinguish primary from secondary hypogonadism, and assessment for reversible causes such as obesity, opioid use, or sleep apnea. [1]

Primary vs. Secondary Hypogonadism

Primary hypogonadism (testicular failure) produces low testosterone with high LH and FSH. Secondary hypogonadism (hypothalamic-pituitary dysfunction) produces low testosterone with low or inappropriately normal LH and FSH. [1] Derek has discussed both categories on his channel and has referenced his own case as secondary in nature, meaning the pituitary signal to produce testosterone is insufficient rather than the testes themselves failing. Secondary hypogonadism is increasingly recognized in younger men and may be associated with prior anabolic steroid use, which can suppress the hypothalamic-pituitary-gonadal axis. [6]

A 2021 review in Translational Andrology and Urology noted that prior anabolic-androgenic steroid (AAS) use is among the most common reversible causes of secondary hypogonadism in men under 50 presenting to andrology clinics, and that spontaneous recovery can take 12 to 24 months after cessation but may be incomplete. [6] Derek has addressed this mechanism directly on his channel, stating that his axis did not recover adequately after prior use. That framing is consistent with the clinical literature, though it remains self-reported.

When TRT Is and Is Not Indicated

The Endocrine Society guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [1] The guideline explicitly advises against TRT in men who are attempting to father children in the near term, have untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, or a hematocrit above 50%. [1]

These contraindications rarely appear in influencer TRT discussions, including Derek's, with the same prominence given to the benefits. That gap is worth flagging for any reader considering TRT after consuming educational content.

What TRT Protocols Actually Look Like Clinically

Most clinical TRT protocols fall into one of three delivery categories: injectable testosterone esters, transdermal gels or patches, or long-acting injectable formulations. Derek primarily discusses injectable testosterone cypionate and enanthate, which are the most commonly prescribed forms in North America.

Injectable Testosterone Esters

Testosterone cypionate and enanthate are esterified forms that extend the half-life of testosterone after intramuscular or subcutaneous injection. Cypionate has a half-life of approximately 8 days; enanthate is slightly shorter at 4 to 5 days. [5] Clinical protocols commonly use 100 mg weekly or 50 mg twice weekly for replacement, targeting a trough testosterone of 400 to 600 ng/dL. Peak-to-trough variation is larger with weekly dosing, which is one reason Derek and many clinicians advocate twice-weekly injections for symptom stability.

Transdermal Options

Testosterone gels (Androgel 1.62%, Testim, Vogelxo) and patches (Androderm) produce more stable diurnal profiles than weekly injections but carry a skin-transfer risk to partners and children. [5] They are preferred by some clinicians for men who prefer to avoid injections or who have needle-related barriers.

Monitoring Hematocrit

The most common serious adverse effect of TRT is erythrocytosis (hematocrit above 54%), which increases blood viscosity and thrombotic risk. The Endocrine Society recommends stopping or reducing TRT if hematocrit exceeds 54% until it normalizes. [1] Injectable testosterone raises hematocrit more than transdermal forms, with one RCT finding a 5.8 percentage point mean increase from baseline over 12 months of injectable TRT versus 3.2 points for transdermal. [7]

Why the Influencer-to-Clinic Pipeline Matters

Derek's channel, along with those of the peers described above, functions as a first point of contact with TRT information for a large number of men. Survey data on where men learn about TRT before consulting a physician are limited, but a 2022 study in the Journal of Sexual Medicine found that 41% of men presenting to andrology clinics for testosterone evaluation cited online video content as a primary information source. [8] That figure highlights both the opportunity and the responsibility carried by high-reach TRT educators.

The Risk of Normalizing Supraphysiologic Use

One concern specific to the MPMD channel, which Derek himself has acknowledged, is that detailed discussion of bodybuilding-level dosing alongside TRT information can blur the distinction for less-informed viewers. He has addressed this directly by labeling historical content about higher-dose use as distinct from his current TRT protocol. That editorial discipline is not universal among fitness influencers, and it represents a meaningful difference in content responsibility.

The Value of Bloodwork Literacy

One area where Derek's content adds documented clinical value is bloodwork interpretation. Teaching an audience to read a testosterone panel, understand the difference between total and free testosterone, and recognize why SHBG levels affect the interpretation of total testosterone results is genuinely useful pre-consultation education. Free testosterone, calculated from total testosterone and SHBG, may be more clinically informative than total testosterone alone in men with abnormal SHBG. [1] A man with a total testosterone of 420 ng/dL but very high SHBG may have less bioavailable androgen than a man with 320 ng/dL and low SHBG.

Safety Considerations Across the Peer Group

None of the public figures discussed here are, to the knowledge of this article's authors, practicing physicians. Their disclosures are educational rather than prescriptive. The risks of acting on influencer TRT content without formal clinical evaluation include misdiagnosis, missing a reversible cause of low testosterone, inappropriate treatment of age-related decline, and exposure to unmonitored erythrocytosis, dyslipidemia, or infertility.

A 2019 analysis in JAMA Internal Medicine found that testosterone prescribing in the United States increased 320% between 2001 and 2011, driven partly by direct-to-consumer advertising and online information, and that a substantial proportion of treated men had not had a pre-treatment testosterone measurement. [9] Content creators who emphasize testing before treatment, as Derek consistently does, are working against that trend. Content creators who minimize the diagnostic requirements are not.

The American Urological Association and the Endocrine Society both recommend that TRT never be initiated based on symptoms alone, without confirmed low serum testosterone. [1] That standard is worth repeating clearly: symptoms of fatigue, low libido, and poor recovery are nonspecific and have many non-hormonal causes.